BO41932
Trial Overview
Official Title
TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL
Study Purpose
To explore a diverse range of both investigational and off-label FDA-approved drugs, each targeting a unique mutation.
Diagnosis
Patients who have advanced and unresectable or metastatic solid tumors that have been found to have specific genetic mutations.Eligibility
Confirmed biomarker mutation, and disease progression on prior treatment, or previously untreated disease with no available acceptable treatment.
Intervention
Arm A: Entrectinib
Arm B: Entrectinib
Arm C: Alectinib
Arm D: Atezolizumab
Arm E: Ipatasertib
Arm F: Trastuzumab Emtansine
Arm H: Inavolisib
Arm I: Belvarafenib
Arm J: Belvarafenib
Arm K: Pralsetinib
Arm L: GDC-6036
Arm M: Camonsertib
Arm N: Camonsertib
For more information, visit Clinicaltrials.gov
Key Participation Requirements
Trial Location(s)
Gender
Male or Female
Age
All ages
Enrollment Status
Recruiting
Phase
Phase II
Methodist Health System Trial Code
BO41932